InterCure receives Nasdaq delisting warning for minimum bid price non-compliance

summarizeSummary

InterCure Ltd. received a Nasdaq notification for failing to meet the minimum bid price requirement, initiating a 180-day period to regain compliance and potentially considering a reverse share split.

check_boxKey Events

• Nasdaq Minimum Bid Price Notification

  On February 25, 2026, InterCure Ltd. received a notice from Nasdaq indicating non-compliance with Listing Rule 5450(a)(2) because its ordinary shares traded below $1.00 for 30 consecutive business days.

• 180-Day Compliance Period Granted

  The company has been granted a 180-calendar day period, until August 24, 2026, to regain compliance. To do so, the closing bid price must meet or exceed $1.00 per share for at least 10 consecutive business days.

• Potential Reverse Share Split Considered

  InterCure intends to monitor its share price and is considering effecting a reverse share split, subject to corporate and regulatory approvals, as part of its plan to regain compliance.

auto_awesomeAnalysis

InterCure Ltd. has received a formal notification from Nasdaq regarding its non-compliance with the minimum bid price requirement, as its stock has traded below $1.00 for 30 consecutive business days. This is a significant negative development as it signals potential delisting from the Nasdaq Global Market, which could severely impact the company's liquidity and investor confidence. While the company has a 180-day compliance period and plans to consider a reverse share split, this action is often viewed negatively by investors as it can be a cosmetic fix that doesn't address underlying business issues and can sometimes lead to further price erosion. Investors should monitor the company's progress in regaining compliance and the potential impact of any reverse share split.